A study published yesterday in Clinical Infectious Diseases described 5 cases of the disease in pregnant women,painting a grim picture of maternal and fetal outcomes.See CIDRAP and read the article titled " As more Saudi MERS noted, study details risks in pregnant patients"
Just a quick note. On June 20th I posted that a new clade of MERS was discover in Saudi Arabia in 2015 and the virus continues to circulate. So, yes the Saidi's are concerned and rightly so. The MERS virus appears to continue mutating and eventually the Saudi government will need to address the problem.
wily, keep the word "universal" in the back of your mind. The NP technology could lead to a breakthrough in the future, but not the near future.
The new NP tech should be able to target multiple HA's along with conserved epitopes and higher immunogenicity.
It looks as if the NP tech is applicable to advances in what can be done with antibodies to produce an immune response. In fact immunotherapies are being used to make the immune system better able to spot and combat different cancers. However, specific targeting has a problem because of antigen binding. Recently new antibody targets have discovered in which NP technology maybe able to exploit. To me this could be another incentive for a suitor to buyout nvax.
cklau, after reading the PR which reiterates what I tried to present, I'm pleased as punch, only because it's an important advancement, and allows nvax to compete in the next phase of development to producing a universal influenza vaccine.
cklau, the current emphases is on influenza vaccines and their cross reactions with different strains of flu's Erck promised an update on advances made with nanoparticles by the end of May, but he hasn't produced it yet. He should shortly because of the risk that future pronouncements by him will not be taken seriously.
Nanoparticle influenza vaccines have been in development for several years with the NIH and Sanofi working together jointly since at least 2013. Earlier this year Sanofi produced a PR in which they stated that their nanoparticle developmental vaccine produced a high immune response against many strains of influence and to that point likened the vaccine as a step to making a universal flue vaccine.
One of nvax's platforms is based on miscelle nanopartices and we know of their use in several vaccines. ie RSV, Ebola etc. and now that nvax has decided to emphasize their development in influenza the question begs as to what stage of development are they at compared to other companies such as Sanofi? and or does the platform offer them advantages that others are yet to posses?
We are in the right place,at the right time, and in the right field.
ACP, other medical groups urge Congress to prevent Zika public health emergency
AMERICAN COLLEGE OF PHYSICIANS
SHARE PRINT E-MAIL
(Washington, May 26, 2016)--The American College of Physicians (ACP) along with the American Academy of Family Physicians (AAFP), the American Academy of Pediatrics (AAP) and the American Congress of Obstetricians and Gynecologists (ACOG) sent a letter today to House and Senate leaders urging them to immediately pass legislation that would provide the highest possible funding level for research, prevention, control, and treatment of illnesses associated with the Zika virus that is commensurate with the public health emergency that the virus represents.
The Zika virus has the potential to rapidly become a public-health emergency that poses a grave risk to patients, especially to pregnant women and their fetuses who may be at risk of severe birth defects, and more broadly, to women of child-bearing age who may become pregnant. Time is of the essence in stemming the spread of this virus. Illness brought on by the Zika virus is rising rapidly by the exposure of travelers returning to the mainland U.S. and soon the country will be entering the summer months when mosquitos that carry and transmit the virus will be proliferating.
Congress is working on legislation to address the Zika issue; however, those efforts have not yet yielded an agreement that would deliver the funding and resources necessary to fully and robustly respond to the Zika virus.
"It is imperative that the House and Senate reach an agreement without further delay; every day that goes by without an agreement is a day where more patients will be at risk of being exposed to the virus," the letter warned.
The letter also stated that while developing a Zika response is critical, that Congress should exercise caution so that funding for other essential health initiatives is not placed at risk in order to fund the response.
When monies are appropriated this concept should help nvax design a vaccine agains the Zika virus.
PUBLIC RELEASE: 19-MAY-2016
Zika virus protein could be vaccine target
NIH/NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
SHARE PRINT E-MAIL
IMAGE: TRANSMISSION ELECTRON MICROSCOPE IMAGE OF NEGATIVE-STAINED, FORTALEZA-STRAIN ZIKA VIRUS (RED), ISOLATED FROM A MICROCEPHALY CASE IN BRAZIL. THE VIRUS IS ASSOCIATED WITH CELLULAR MEMBRANES IN THE CENTER. view more
A viral protein known as NS5 is a promising target for vaccines against Zika and related viruses, according to National Institutes of Health (NIH) scientists and colleagues at Mount Sinai's Icahn School of Medicine. Their study, published online May 19, 2016 in Cell Host & Microbe, suggests that altering or removing the NS5 protein from Zika virus would allow the human body's own immune defenses to attack the virus. The study found that NS5 prevents Zika virus-infected human cells from signaling immune system cells to make interferon, a powerful antiviral protein.
The researchers previously found that NS5 plays a similar interferon-blocking role for other members of the flavivirus family, most notably dengue virus and West Nile virus. The current study extends those findings to four other little-known viruses. Each virus appears to have evolved differently, they say, and uses a different NS5 mechanism to alter the host immune response. The researchers, including a group from NIH's National Institute of Allergy and Infectious Diseases, noted that one of the viruses they examined--Spondweni virus--has the potential to emerge as a human pathogen. Spondweni, a close relative of Zika virus, is spread by mosquitoes in sub-Saharan Africa and Southeast Asia.
With Zika virus, their study details how NS5 specifically inhibits human interferon responses by blocking the STAT2 protein, which is essential for signaling an interferon resp